ECCO essential requirements for quality cancer care: Melanoma
- PMID: 29458785
- DOI: 10.1016/j.critrevonc.2017.12.020
ECCO essential requirements for quality cancer care: Melanoma
Abstract
Background: ECCO essential requirements for quality cancer care (ERQCC) are explanations and descriptions of challenges, organisation and actions that are necessary to give high-quality care to patients who have a specific type of cancer. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements needed in any healthcare system to provide high quality of care throughout the patient journey. References are made to clinical guidelines and other resources where appropriate, and the focus is on care in Europe.
Melanoma: ESSENTIAL REQUIREMENTS FOR QUALITY CARE: CONCLUSION: Taken together, the information presented in this paper provides a comprehensive description of the essential requirements for establishing a high-quality service for melanoma. The ERQCC expert group is aware that it is not possible to propose a 'one size fits all' system for all countries, but urges that access to multidisciplinary teams and specialised treatments is guaranteed to all patients with melanoma.
Keywords: Audit; Cancer centre; Cancer unit; Care pathways; Essential requirements; Europe; Guidelines; Health inequalities; Healthcare system; Melanoma; Multidisciplinary; Multidisciplinary team; Organisation of care; Patient information; Patient-centred; Quality; Quality assurance.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer.Crit Rev Oncol Hematol. 2018 Feb;122:179-193. doi: 10.1016/j.critrevonc.2017.12.019. Epub 2018 Jan 2. Crit Rev Oncol Hematol. 2018. PMID: 29458786 Review.
-
ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review.Crit Rev Oncol Hematol. 2017 Feb;110:94-105. doi: 10.1016/j.critrevonc.2016.12.002. Epub 2016 Dec 8. Crit Rev Oncol Hematol. 2017. PMID: 28109409 Review.
-
ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review.Crit Rev Oncol Hematol. 2017 Feb;110:81-93. doi: 10.1016/j.critrevonc.2016.12.001. Epub 2016 Dec 8. Crit Rev Oncol Hematol. 2017. PMID: 28109408 Review.
-
ECCO Essential Requirements for Quality Cancer Care: Prostate cancer.Crit Rev Oncol Hematol. 2020 Apr;148:102861. doi: 10.1016/j.critrevonc.2019.102861. Epub 2020 Jan 7. Crit Rev Oncol Hematol. 2020. PMID: 32151466 Review.
-
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer.Lung Cancer. 2020 Dec;150:221-239. doi: 10.1016/j.lungcan.2020.08.017. Epub 2020 Sep 4. Lung Cancer. 2020. PMID: 33227525 Review.
Cited by
-
Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine.Eur J Nucl Med Mol Imaging. 2024 Feb 6. doi: 10.1007/s00259-024-06633-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38319322 Review.
-
Long-Term Temporal Trends in Survival Among Danish Patients with Advanced Cutaneous Melanoma: A Nationwide Follow-Up Study.Clin Epidemiol. 2023 Jun 15;15:733-742. doi: 10.2147/CLEP.S407060. eCollection 2023. Clin Epidemiol. 2023. PMID: 37342868 Free PMC article.
-
Survival in melanoma in the nordic countries into the era of targeted and immunological therapies.Eur J Cancer. 2023 Jun;186:133-141. doi: 10.1016/j.ejca.2023.03.019. Epub 2023 Mar 24. Eur J Cancer. 2023. PMID: 37068406 Free PMC article.
-
Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective.Front Oncol. 2023 Mar 14;13:1032300. doi: 10.3389/fonc.2023.1032300. eCollection 2023. Front Oncol. 2023. PMID: 36998456 Free PMC article. Review.
-
A randomised trial probes the higher efficacy of a hybrid radioactive and fluorescent tracer approach in high-complexity sentinel node biopsy during robotic surgery of prostate cancer.Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2588-2590. doi: 10.1007/s00259-023-06213-4. Eur J Nucl Med Mol Imaging. 2023. PMID: 36961536 Clinical Trial. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
